TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07779798: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Ad

Sponsor: Crossbow Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07779798 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07779798 Rescue Dossier →